^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Renal Cell Carcinoma
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor) +
    Tecentriq (atezolizumab) (PD-L1 inhibitor) +
    eganelisib (IPI-549) (PI3Kγ inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3) (MARIO-3)

    Excerpt:
    Evaluable tumor tissue (archived [without time constraints] or new biopsy) must be provided for biomarker analysis, which will include PD-L1 expression level using immunohistochemistry (IHC) to measure specific PD-L1 signals in tumor-infiltrating immune cells (ICs).
    Trial ID:
    MARIO-3